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ABSTRACT 
Postpartum Depression (PPD), part of a larger spectrum of Perinatal Mood and Anxiety 
Disorders, affects up to 15% of women following the birth of an infant. Fathers may also be 
affected. PPD not only affects caregivers, but also impacts infants through mechanisms such as 
inadequate caregiver-infant interactions and non-adherence to safety practices. The negative 
impact on infants may extend across the life course through adulthood. This article seeks to 
move the needle toward universal screening for PPD using validated tools in pediatric primary 
care settings for new caregivers by making the legal and ethical case for this course of action in a 
manner that is both compelling and accessible for clinicians. Toward this end, we summarize 
current literature as it applies to provider responsibilities, liabilities and perspectives; and 
caregiver autonomy, confidentiality and privacy. We then assess utility by balancing the benefits 
and burdens of this approach to practices, providers and caregivers; and take the analysis one 
step further by extending looking across multiple populations to assess distributive justice.  We 
conclude that there is a strong ethical case for universal screening for PPD in pediatric primary 
care settings using validated tools when informed consent can be obtained and appropriate 
follow-up services are available and accessible. Clinical considerations, practical resources and 
areas ripe for future research are also addressed. 
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BACKGROUND  
Overview of Postpartum Mood and Anxiety Disorders and Their Impact   
Postpartum depression (PPD) affects up to 15% of women following the birth of an infant. 
PPD is a part of a larger spectrum of postpartum mood and anxiety disorders, or PMADs.1,2 
Postpartum anxiety is a separate condition that affects up to 18% of all mothers, making it 
equally worrisome, that can occur separately or combined with PPD3. The risk of PPD is more 
common within the first four months postpartum, but can occur anytime during the first year. 
Having a prior or family history of depression, being a teen mother or experiencing stressful 
situations, such as living in poverty or limited social support, are known risk factors of PPD. In a 
prospective cohort study, thoughts of death and dying or difficulty falling asleep at one month 
postpartum were associated with PPD at four months4. Fathers can also develop symptoms of 
PPD, but these often go undiagnosed.5,6 PPD not only affects caregivers, but also frequently 
results in inadequate caregiver-infant interactions and non-adherence to safety practices.7 The 
negative impact on infants may extend into early childhood,8–10 resulting in a higher risk of 
developmental delays and behavioral issues. Exposure to parental mood disorders is one of ten 
known Adverse Childhood Experiences, or ACEs11, that have been shown to be associated with 
poor health, social and behavioral outcomes spanning the life course. It is therefore important to 
screen and identify at-risk individuals early, so caregivers experiencing PMADs can receive 
appropriate treatment and support in a timely manner. 
  
Overview of Current Screening Practices and Tools 
In the past, screening for PPD and other PMADs fell largely to adult medicine primary 
care providers including family practitioners, obstetricians and internists. In recent years, 
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however, there has been increasing recognition that pediatric primary care providers have a 
unique opportunity to identify PMADs. Most of the research informing this recognition has been 
focused on mothers and PPD. It is recommended that at least 8 well-child visits occur during the 
first year of a child’s life, resulting in earlier and more frequent interactions with new mothers.12 
Research also shows that women report a host of issues accessing healthcare for themselves, 
such that screening for PPD in pediatric settings may be the only way to catch them in the busy 
first year of their children’s lives.13 Although not all women are able to attend every 
recommended well-child visit, mothers may be more likely to seek care for their children than 
they would for themselves, and be more honest in their responses when screening is put in the 
context of benefiting their child’s health.14  
 While many healthcare providers report feeling confident in their ability to identify PPD 
informally through conversations and general impressions,15–17 surveillance of this nature has 
been found to be significantly less effective than screening with a validated tool. 17–19 Support for, 
and adoption of, screening for PPD by pediatric primary care providers using validated tools 
during well-child visits in the first year of life is increasing.  A number of studies have 
demonstrated the feasibility and success of this approach 12,20–22 and several professional 
organizations and government agencies including the United States Preventive Services Task 
Force (USPSTF),23 American Academy of Pediatrics (AAP),12 and Centers for Medicare and 
Medicaid Services (CMS)24 support this movement (See Table 1: Support for Screening in 
Pediatric Settings with Validated Tools). 
 The most commonly used tools for identifying symptoms of PPD are the Edinburgh 
Postnatal Depression Scale (EPDS) and the Patient Health Questionnaire (PHQ-2 or PHQ-
9).  These instruments have been widely accepted, translated into more than twenty languages, 
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and validated for a variety of patient populations including the EPDS for adolescent mothers25 
and fathers26,27.  Either tool can reliably be used in the context of screening for PPD among 
postpartum mothers, as scores using the PHQ or EPDS have been shown to be concordant.28 
However, the EPDS specifically includes 3 items to capture anxiety symptoms (feeling 
scared/panicky, anxious or worried, and blamed self unnecessarily); whereas the PHQ is specific 
to depressive symptoms only29. Thus, the choice of which screen to use may ultimately be based 
upon provider preference. Depending on the particular population being screened, sensitivity for 
the EPDS ranges from 0.63 to 1.00 with specificity typically between 0.78-0.87.30,31 Similarly, 
the PHQ-2 sensitivity ranges from 0.75 to 1.00 with specificities between 0.62 to 0.8832 and for 
the PHQ-9 sensitivity is 0.75 and specificity of 0.91.32 The EPDS has been used and studied 
more extensively than the PHQ-2 or PHQ-9 among postpartum women,30 but all of these tools 
show promising results. Average screening times have been shown to be less than 3 
minutes21,22,33 with most conversations lasting less than 3 minutes22 and providers requiring less 
than one minute to score and interpret the results.21 It is important to note that all of these tools 
are to be used for screening, and not diagnostic, purposes.22 
 
Table 1: Support for Screening in Pediatric Settings with Validated Tools 
Organization Recommendations/Support Tool Endorsed 
American Academy 
of Pediatrics / Bright 
Futures 
Guidelines12,34 
Maternal depression screening at 1, 2, 4, and 
6 month visits 
EPDS 
PHQ-2 
PHQ-9 
US Preventive Grade B recommendation: Pregnant and Provides evidence review 
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Services Task Force 
Recommendation 
Statement23,30  
postpartum women should be screened and 
supported with treatment and follow-up 
when necessary (support for this population 
to be screened in either obstetric or pediatric 
settings) 
for both EPDS and PHQ 
Centers for 
Medicare & 
Medicaid Services 
(CMS)24 
Some State Medicaid agencies cover PPD 
screening at well-child visits through either 
the mother’s or child’s Medicaid ID (via the 
Early and Periodic Screening, Diagnostic 
and Treatment component of Medicaid). 
Examples include: 
• Colorado35 
• Illinois36 
• Minnesota37 
• North Dakota38 
• Virginia39 
Vary by state, but include 
EPDS, Beck Depression 
Inventory-II (BDI-II), 
Center for 
Epidemiological Studies 
Depression Scale (CES-
D), PHQ-9, Parenting 
Stress Index (PSI) 
National 
Association of 
Pediatric Nurse 
Practitioners 
(PNPs)40 
States that PNPs are “skillful in screening 
mothers for risk of maternal depression” and 
supports early interventions to promote 
psychological well-being for parents 
N/A 
Mental Health 
America41 
Supports screening for PMADS in a variety 
of settings including pediatrics. Also states 
N/A 
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that the cost of screening and follow-up care 
should be covered in all health plans and 
encourages the co-location of mental health 
professionals in settings where screenings 
occur  
 
A previous analysis conducted by Chaudron et al. in 2007 looked at the basic question of 
whether or not screening for postpartum depression at pediatric primary care visits was legally 
and ethically justified, and determined that it was.42 Why, then, in light of this analysis and the 
recommendations of so many professional organizations are we still talking about screening for 
PPD and other PMADs in pediatric settings rather than consistently practicing and teaching this 
approach? Unfortunately, recent reviews demonstrate that there is still considerable room for 
improvement. Although the proportion of pediatricians who report usually inquiring about or 
screening mothers for PPD has increased significantly in the past decade from 33% to 44%, the 
fact that this number remains so low is concerning. 43 Moreover, once PPD is suspected, less 
than half of those with positive screens receive referrals to mental health services21 - an ethically 
problematic and avoidable state of affairs that leaves both infant and caregiver in harms way.  
 
Making the Legal and Ethical Case for Universal Screening in Pediatric Primary Care 
This article seeks to move the needle forward even further by making the legal and 
ethical case for universal screening for PMADs using validated tools in pediatric primary care 
settings for new caregivers of infants in a manner that is both compelling and accessible for 
clinicians. Our approach will be to summarize the current literature and apply a series of 
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guidelines deemed important to determining whether a proposed clinical or public health 
initiative is ethical. These guidelines call for: (1) maximizing benefits while minimizing burdens; 
(2) assessing the likelihood of effectiveness, voluntariness of the intervention, and distributive 
justice; (3) respecting patient and parent autonomy, privacy, and confidentiality; (4) considering 
the responsibility and liability of the provider; and (5) seeking input from all stakeholders.44,45 
We will then state our conclusions, make specific recommendations for establishing a universal 
standard of care, and identify areas in need of further research. 
 
LEGAL AND ETHICAL CONSIDERATIONS 
As we think through the legal and ethical case for screening mothers for PMADs in 
pediatric primary health care settings, precedent can be helpful. For this reason, we will not only 
draw from literature that pertains to health care surveillance and screening for PPD, the most 
studied of all PMADs, but also highlight literature that focuses on screening parenting adults for 
other health or psychosocial risk factors that have the potential to impact the health of the child. 
It is important to note up front that screening in these cases places a burden on the caregiver 
alone for a benefit that ultimately accrues to both the caregiver and child.  In circumstances such 
as this, it is ethically imperative that positive screens be followed up with support for both the 
caregiver and child12,44 Italicized terms throughout this section have been defined below in Table 
2: Relevant Legal and Ethical Terms. 
 
Table 2: Relevant Legal and Ethical Terms 
Term Definition 
Fiduciary Duty Providers have an elevated legal duty to exercise the highest standard of 
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loyalty and care to patients by virtue of their control over important subject 
matter, the vulnerability of patients, and the resulting potential for abuse46. 
Beneficence A provider’s obligation to act in a manner that benefits a patient, especially 
with regard to the patient’s health. The three obligations of beneficence 
include preventing evil or harm, removing evil or harm, and promoting 
good.47 
Non-Maleficence Often considered a fourth obligation of beneficence, non-maleficence 
mandates that a provider ought not inflict evil or harm.47 
Autonomy The right of a patient to make informed decisions regarding his or her own 
healthcare. The five components of respecting a patient’s autonomy 
include: telling the truth, respecting privacy, protecting confidential 
information, obtaining consent, and providing support for decision-making 
when asked.47 
Informed Consent Requires that a patient be informed of the harms and benefits of the 
proposed course of action, that the patient have the capacity to understand 
the information and make a decision, and that the patient have a clear 
understanding that the proposed course of action may be accepted or 
declined.47 
Confidentiality The duty of a provider to maintain secrecy regarding a patient’s health 
information absent patient consent to disclose or a legally mandated duty to 
breach46. 
Privacy The right of patients to make decisions about how their personal 
information is shared48. 
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Utility The principle of maximizing benefit while minimizing burden or harms.49 
Distributive Justice A specific component of justice where social benefits and burdens should 
be equally realized throughout the community or population, regardless of 
disease status or demographic factors.47  
 
Responsibilities, Liabilities and Perspectives of the Pediatric Primary Care Provider 
The inherently unequal distribution of power in the relationship between healthcare 
providers and patients gives rise to providers having a fiduciary duty to their patients. In the 
simplest of terms, this means that providers have a legally heightened responsibility to provide 
the best and most honest care possible to their patients47 due to their elevated knowledge and the 
relative vulnerability of their patients.46 In pediatrics, this means that providers have a duty to 
make the child’s interests paramount by providing direct care, making appropriate referrals, and 
generally doing what is in the best interest of the child. Because children are minors, and 
therefore lack the capacity to understand and consent to their own healthcare in most instances, 
we as a society have deemed parents or legal guardians responsible for making healthcare 
decisions on their behalf. For this reason, a pediatric provider’s fiduciary duty extends beyond 
the child to include a responsibility to disclose relevant information to the parent or legal 
guardian about factors that may ultimately impact the child’s health, so that the best care possible 
may be provided to the child.    
 
The bioethical principles of beneficence and non-maleficence further elucidate a 
provider’s responsibility to do no harm, prevent evil or harm, remove evil or harm, and promote 
good.47 If a provider screens for, and identifies, symptoms of a PMAD, he or she has an ethical 
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responsibility to refer or otherwise connect that caregiver to appropriate services and care so as 
to avoid harm, and promote wellbeing, of both the infant and the caregiver. 12 It is important to 
note that providers are increasingly being asked to screen caregivers in pediatric primary care for 
a number of environmental and psychosocial risks to children including poverty, family support 
systems, and parental substance use.12 These risk factors, along with PMADs, are part of a larger 
group of increasingly recognized ACEs, which have been shown to have a dose-response 
association with negative health outcomes throughout the life course.11 This movement toward 
screening for social determinants of health in clinical settings has the potential to significantly 
improve child health, but providers have not necessarily been quick to adopt it for a variety of 
reasons.50 In a recent survey of pediatricians, 57% considered PPD screening within the scope of 
their practice, but only 45% felt confident in their ability to identify PPD or provide appropriate 
support to mothers.15 Pediatricians attributed reservations about screening to a lack of training, 
low confidence in their ability to correctly use screening tools and interpret results, and limited 
knowledge about the adult mental health resources available in their communities.15,16   
 Medical liability, or a provider’s legal responsibility for an adverse patient outcome, is 
another topic that clinicians frequently express concern about in the context of screening 
caregivers for PMADs in pediatric settings. Medical liability or malpractice laws vary 
significantly by state,51 but in very general terms liability hinges on whether or not a given 
provider exercised reasonable care and skill in a manner consistent with an established standard 
of care.46 In a legal setting, complexity is likely to arise if the caregiver, as opposed to the patient, 
is the one to suffer damage – and if a clear standard of care has not yet been established. These 
complexities highlight the importance (described in more detail below) of obtaining informed 
consent from caregivers prior to screening, and developing an established standard of care for 
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screening in pediatric settings that spans both individual practice locations and the field at large. 
In summary, an argument can be made that pediatric primary care providers have an ethical 
responsibility to screen for PMADs and consider screening to be within their scope of care. This 
responsibility, however, appears to be at odds with their sense of discomfort around screening, 
management and risk of liability. This discordance may best be resolved with education, which 
will be discussed in more detail below.  
 
Caregiver Autonomy, Confidentiality, and Privacy 
Very rarely can we justify infringing on one person’s rights to help another, particularly 
if little benefit accrues to the infringed person, but screening for PMADs clearly has the potential 
to not only benefit the child, but also the caregiver. Autonomy is a term used to describe both a 
patient’s right to make his or her own healthcare decisions, and a provider’s responsibility to 
acknowledge and protect that right (see Table II: Relevant Legal and Ethical Terms). In the 
context of screening a caregiver for risk factors that may impact a child’s health, the caregiver’s 
autonomy must also be respected. Although obtaining informed consent from a caregiver prior to 
screening for risk factors that may impact the health of a child is not standard practice, respect 
for autonomy supports the position that caregivers should be presented with information about 
the screening process, informed of any known potential benefits and harms (to both the caregiver 
and the child), and then offered a choice to participate in screening (or not). Without consent, 
screening has the potential to become coercive and paternalistic, and the practice may in fact 
undermine a caregiver’s trust in his or her child’s provider and sabotage open communication. A 
few practical considerations related to obtaining consent from caregivers in pediatric settings 
include state-specific legal requirements regarding capacity to consent, whether the consent is 
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written or verbal, what the benefits and risks of screening and documentation of screening 
actually are in the particular setting, and how and where the receipt of consent will be 
documented (e.g., the child’s medical record). 
 Confidentiality refers to the professional responsibility of providers, who have access to 
both medical records and patient communications, to hold patient information in confidence.46,52 
When discussing the personal health information of patients - including risk exposures such as 
PMADs - with parents or legal guardians, information provided by these caregivers is likewise to 
be held in confidence. One notable limit to confidentiality that may arise in the context of 
screening for PMADs includes mandatory reporting to law enforcement in the case of suspected 
child maltreatment or, in some states, exposure of a child to caregiver-reported or suspected 
intimate partner violence. This legal requirement to breach confidentiality in certain 
circumstances is one that providers should share with caregivers in the process of obtaining 
informed consent.  
In contrast to confidentiality, privacy (as it is understood in the context of federal privacy 
regulations such as the Health Information Portability and Accountability Act) refers to the right 
of patients to make decisions about how their personal information, including personal health 
information, is shared.48 Parents and legal guardians have the right to make decisions about how 
information is disclosed on behalf of their children, including the sharing of medical record 
information such as documentation of risk exposures like PMADs. It is important to remember 
that all legal guardians of a given pediatric patient have access to, and can direct the sharing of, 
personal information contained in that patient’s medical record. For this reason, it is important to 
be mindful of the impact that documenting a positive PMAD screen for one guardian may have 
when there is reason to believe the other guardian might try to access and use that information in 
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a damaging way. Again, this privacy caveat is one that should be shared with caregivers in the 
process of obtaining informed consent. Given the limits of both confidentiality and privacy, it is 
important for practices to carefully consider what should be documented in the patient’s medical 
record in light of the particular populations served and the relevant laws of the state. Whereas 
some practices may choose only to document that a screening tool was administered, others may 
also elect to include details about scoring, referrals and follow-up. 
 
Utility – Balancing the Benefits and Burdens 
Utility is defined as maximizing the benefits of a particular intervention while 
minimizing its burden.  When considering the implementation of a new clinical initiative, utility 
should be evaluated and modifications made as necessary to improve the benefit to burden ratio. 
The following paragraphs briefly summarize the known benefits and burdens of screening for 
PMADs in pediatric primary care settings using validated tools, and then consider the utility of 
implementing this practice on a widespread scale.  
Benefits. Utilization of validated brief screening instruments allows providers to detect 
worrisome signs and symptoms early when PMADs are present or emerging so they may be 
treated more easily. The use of screening tools to jump start conversations may also serve to 
establish therapeutic alliances between providers and caregivers, helping caregivers understand 
that providers may be trusted sources of parenting support. Routine preventive care visits present 
providers with an ideal opportunity to discuss concerns related to an infant’s growth and 
development, as well as provide critical parenting support for new caregivers. As there are 
approximately eight recommended visits in an infant’s first year,34,53 pediatric providers are well-
positioned to monitor caregiver mood, observe caregiver-infant interactions and administer 
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screening.12,21,22,42,53,54 Once a caregiver screens positive for PMAD symptoms, knowledgeable 
providers can ensure timely referrals for additional diagnostic evaluation and evidence-based 
supportive services. For providers working within a co-located family practice model or within 
an integrated behavioral health care practice, pediatric providers can collaborate directly with 
mental health providers to provide coordinated services within the medical home. Provision of 
universal screening and timely services for support and treatment benefit not only the caregiver, 
but also the child.  
 Burdens. The costs of screening may be economic or otherwise, and may accrue to the 
healthcare provider, practice, or caregiver. To the practice and provider, direct costs include 
monetary outputs associated with screening (e.g., printing for paper-based screening, algorithm 
development and hardware costs for electronic screening, and data management) and indirect 
costs such as provider training, provider time and any other resources necessary to redesign the 
clinical flow.16,18 While these costs are important and sometimes cited as barriers to screening, 
the actual time required for screening and scoring is minimal, as previously described, and many 
of the tools themselves are free to use and available in the public domain. For example, the PHQ 
tools can be accessed at www.phqscreeners.com, and the EPDS is available online in a number 
of locations. Regarding billing, as of January 2017, CPT Code 96161 may be used to report the 
administration of a caregiver-focused health risk assessment with scoring and documentation, 
using a standardized instrument, for the benefit of the patient (e.g., the EPDS).55  
 In terms of burdens that accrue to the caregiver, the primary cost may be a potential loss 
of confidentiality or privacy as discussed above. Additional concerns include the low positive 
predictive value of screening tools (e.g., estimated around 40% for the EPDS).33 False positives 
can potentially impact the mother by exposing her to unnecessary concern and stigma associated 
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with being labeled as depressed.56,57 False positives may also negatively impact providers and the 
practice by commanding unnecessary investments of time and resources. A majority of studies, 
however, report minimal to no adverse effects of screening on caregivers, and several report on 
no harms at all.23,30,58  
An important consideration in assessing burden is that caregivers themselves report being 
more likely to open up about their own health to their children’s primary care providers when 
they have an established relationship,59 which speaks to there being a lesser burden for some 
caregivers than others. The existence of a trusting relationship is particularly relevant in the 
context of caregivers’ concerns about being judged or reported to child protective services.59 Of 
note, however, one study found that all participating mothers connected their own emotional 
health to their child’s wellbeing, and most believed they had a responsibility to maintain their 
own emotional health for the benefit their child.59 This, along with other studies about mothers’ 
approval of their children’s providers screening for PPD, 13 and a general receptiveness to being 
screened using the EPDS,60 show that there is substantial maternal support for implementing 
screening in this setting.13,61,62 Support for screening among fathers and other caregivers has not 
yet been evaluated to the same extent, highlighting a need for further research in this area. 
 Utility. We first consider utility – the balancing of benefits and burdens – in settings 
where follow-up supports are available versus settings in which they are not. In the case of a 
positive screen in a setting where appropriate services are not accessible for any reason, the 
potential harms (e.g., emotional distress) become considerable and the benefits negligible, 
making screening in this context unjustifiable.44 When appropriate services are available, 
however, the potential for benefit clearly outweighs the risk of harm. Another way of thinking 
this through is in the context of insurance. If a positive screen occurs and the caregiver is referred 
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for services, but that caregiver is either uninsured or underinsured, then he or she may practically 
be unable to access services.12 For this reason, efforts should be made by practices to ensure 
access to follow-up care for all caregivers who screen positive, regardless of insurance coverage. 
Toward this end, some state AAP chapters have taken it upon themselves to take steps toward 
ensuring access within their local jurisdictions.12 
 We next consider utility in situations where screening using a validated tool is universal 
versus situations in which it is not. When screening for PMADs is not universal, either at the 
discretion of the provider or through selective screening of high-risk populations, the utility is 
reduced.  As demonstrated in the literature, informal provider surveillance is often ineffective, 
resulting in a large number of false negatives.17,18,63 Similarly, if providers only screen a 
predetermined sub-population with known risk factors, the providers risk missing symptoms 
among caregivers of other populations and giving those caregivers a false sense of security about 
their risk of PMADs. This issue of distributive justice, and its implications, is discussed in more 
detail below. In contrast, if screening is administered universally to all caregivers of infants in a 
particular practice, providers are most likely to detect PMAD symptoms while not exposing any 
one population to differential harm thus maximizing utility across populations in a just manner. 
 To summarize, from an ethical standpoint, the utility of screening for PMADs is 
maximized when informed consent is obtained and universal screening is conducted using a 
validated screening tool in practices where appropriate follow-up services can be provided or 
referred. In such situations, the harms have been shown to be minimal or nonexistent and the 
benefits to mother and child are significant. 18  
  
Justice – Balancing the Benefits and Burdens Across Different Populations 
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The concept of justice in medical ethics refers to the distribution of health resources in a 
fair and equitable manner.47 Distributive justice takes this one step further by requiring a 
balancing of benefits and burdens across a variety of populations, such that no one population 
shoulders significant burden without the potential for significant benefit.47In light of known 
disparities of prevalence and severity of PPD across different caregiver populations, such as 
young, low-income, and single mothers,12,21 justice is an important consideration. Teen mothers, 
in particular, are at elevated risk with prevalence documented as high as 56%.64 While the 
temptation might be to screen only those populations at increased risk in a given practice setting 
because a topical analysis suggests utility may be maximized in this way, doing so would ignore 
a large proportion of caregivers who may likewise be affected. As one public health ethicist 
explained, perhaps the most significant harm that can occur happens when an intervention fails 
to include a certain group of people such that individuals within that group mistakenly believe 
they are not at risk.45 If caregivers feel that they are not at risk for PPD because they have not 
been screened, particularly if they know that others have been screened and/or they have limited 
knowledge about risk factors for PPD, the intervention has done those caregivers harm.20 It is for 
this reason that adhering to professional guidelines, such as the USPSTF recommendation that all 
women be screened for PPD regardless of risk factors when support services are available, is so 
important. 23,45 Striving for distributive justice in the context of screening for PMADs in 
pediatric primary care settings also requires that less-studied populations of caregivers, such as 
fathers and adoptive parents, also be screened – although additional research should be 
conducted to determine whether the benefits and burdens of the intervention differ significantly 
for these populations.  
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A Special Note About Fathers 
Estimates suggest that as many as 10% of new fathers show symptoms of PPD, but there 
is high variability among these estimates.65,66 Most studies suggest that symptoms for mothers 
occur most frequently between 3-6 months after birth,65 and that paternal PPD is highly 
correlated with maternal PPD65,67. Paternal PPD has been shown to have many of the same 
effects on infants as maternal PPD68 – for example, children of fathers who experienced paternal 
PPD are more likely to experience psychiatric diagnoses at 7 years69 - but studies suggest that the 
effects of maternal PPD are more likely to be long-lasting.69,70 In dual-parent households, fathers 
often shield children from the effects of maternal PPD,71–74 but if fathers are also experiencing 
PPD they not only fail to assume this protective role, but the overall effects on the child’s health 
and well-being are also exacerbated.71 While mothers attend preventive care visits more often 
than fathers, fathers should also be screened for PMADs when they do attend. Ethical 
considerations for fathers mirror those of mothers, although utility analyses may differ slightly 
given that the risk of long-term effects are lower with paternal PPD unless both parents are 
experiencing symptoms, in which case the harms are magnified.  Informed consent and universal 
screening practices should apply with equal force to fathers.  
 
CONCLUSIONS, CLINICAL IMPLICATIONS, AND FUTURE DIRECTIONS 
Given the ever-growing evidence base regarding the negative effects of adverse 
childhood experiences on early brain and child development and implications for poorer health 
over the life course8–11, professional organizations increasingly recommend that pediatric 
providers implement universal screening for PPD and other PMADs at key preventive care 
visits.12,23,30,34,40,41 While only a limited number of state Medicaid agencies currently provide 
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reimbursement for screening in this setting,35–39 it is important nonetheless for practices and 
providers to understand that offering universal screening for PMADs in pediatric primary care 
will ultimately lead to improved health outcomes for patients.  
 There are several legal parameters to be mindful of in redesigning the clinical flow to 
implement this process including the limits of confidentiality and privacy, and the hypothetical 
potential for medical liability if a provider fails to exercise reasonable care and skill in a manner 
consistent with the evolving standard of care. Specific documentation requirements, in particular, 
are something that should be carefully considered so as to avoid breaches that may adversely 
impact caregiver safety and wellbeing. These are parameters that will ideally be assessed in the 
clinical redesign process by the practice or system, as opposed to the individual provider, in 
collaboration with someone who understands relevant jurisdictional law and system policies (e.g., 
general counsel or a risk management professional). Other tangible resources for guidance and 
support include working with chapters of professional organizations to advocate for billing and 
reimbursement issues at the state level, or for technical assistance in screening efforts by seeking 
help from the AAP Screening Technical Assistance and Resource Center.  Clinicians can also 
connect with local chapters of national and international non-for-profit organizations such as 
Postpartum Support International (www.postpartum.net) to learn about state-specific resources 
available in local communities.  
Another consideration that is beyond the scope of this article is the role of clinical 
training and professional education in helping to further establish the standard of care by 
providing information about how best to develop a trusting relationship with new caregivers such 
that they feel comfortable with screening, the evidence base for universal screening, the use of 
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validated tools, the necessity of appropriate follow-up, and (in clinical environments) any 
system-specific policies and procedures. 
Lastly, there exist several gaps in the literature related to this topic that invite future 
research, including prevalence rates of PMADs other than PPD for various populations; 
perspectives on screening of fathers and other non-maternal caregivers; the cost effectiveness of 
integrating screening into pediatric practice; and comparative analyses of different 
reimbursement practices to guide future policy.  
In conclusion, although there is much research yet to be done, a strong legal and ethical 
case already exists for implementing universal screening for PMADs in pediatric primary care 
settings using validated tools when informed consent can be obtained and appropriate follow-up 
services are available and accessible. 
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